Renalytix Share Price Rises as UBS Increases Stake and CEO Buys Shares
Renalytix PLC (RENX.L) saw its share price rise by 7% to 6p on Friday, driven by an increase in the stake held by UBS Group. The Swiss bank now holds a voting interest of 6.62%, up from 5.17%, following indirect ownership of approximately 39.9 million shares as reported in a filing dated September 9, 2026. In addition to institutional buying activity, CEO James McCullough purchased 340 American Depositary Shares (ADS) over two days through OTC New York for $1,317.65 total. These purchases increased his stake in the company by an equivalent of 17,000 ordinary shares, bringing his total interest to more than three million shares. The share price movement coincided with continued commercial rollout of Renalytix’s kidney disease risk test, kidneyintelX.dkd, which has secured Medicare reimbursement at $950 per reportable result and is now being offered in selected U.S. regions.
Topics: CEO share purchases Renalytix UBS holdings